Company: LIMN
Filing Date: 2025-06-24
Form Type: S-1
Source: 0001410578-25-001432
Chunk: 236

Company: Liminatus Pharma, Inc.
Filing Date: 2025-06-24
Form: S-1
Chunk 236
---
, basic and diluted | ​ |                                 | 16,666,666 | ​ |   | 16,666,666 |

The accompanying notes are an integral part of these financial statements.

F-38

LIMINATUS PHARMA, LLC STATEMENTS OF CHANGES IN MEMBERS’ DEFICIT FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023 (in thousands, except member unit data)

| ​                                                                        
 ​                                                                        | ​ |                                              ​ 
 For the years ended December 31, 2024 and 2023 | ​ | ​      |     ​ | ​ |                     ​ | ​ | ​      |   ​ | ​ | ​                  |     ​ | ​ | ​           |       ​ | ​ | ​              |       ​ |
|:-------------------------------------------------------------------------|:--|-----------------------------------------------:|:--|:-------|------:|:--|----------------------:|:--|:-------|----:|:--|:-------------------|------:|:--|:------------|--------:|:--|:---------------|--------:|
| ​                                                                        | ​ |                           Class A Member Units |   |        |       | ​ | Class B Members Units |   |        |     | ​ | Additional Paid-in |       | ​ | Accumulated |         | ​ | Total Members’ |         |
| ​                                                                        | ​ |                                          Units |   | Amount |       |   |                 Units |   | Amount |     |   | Capital            |       |   | Deficit     |         |   | Deficit        |         |
| Balance at December 31, 2022                                             |   |                                     57,000,000 | ​ | $      | 4,000 |   |            16,666,666 | ​ | $      | 167 | ​ | $                  | 5,158 | ​ | $           | -20,135 | ​ | $              | -10,810 |
| Cancellation of member units related to Metavagen license termination    |   |                                    -40,000,000 | ​ |        |  -239 |   |                     — | ​ |        |   — | ​ |                    |   239 | ​ |             |       — | ​ |                |       — |
| Issuance of Class A member units in exchange for CD‑47 License Agreement |   |                                     78,555,554 | ​ |        |